Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc. presents an attractive current valuation with potential for significant upside, as indicated by recent net present value analyses reflecting an increase in projected share price. The company's lead program, Stenoparib, demonstrates promising clinical benefits, notably a median overall survival exceeding 25 months for patients involved in its Phase 2 trial, establishing its efficacy for those with limited treatment options. Furthermore, the integration of proprietary Drug Response Predictor technology enhances patient selection and clinical outcomes, positioning the company favorably within the oncology therapeutic landscape.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.8 million, resulting in an EPS of $(0.19), which is marginally better than estimates but still indicative of financial challenges. The company faces significant risks that may impede its growth, including balance sheet and liquidity issues, potential failures in clinical trials, and difficulties in gaining regulatory approvals. Additionally, ongoing market dynamics and competition further compound the uncertainty surrounding the commercial viability of its lead program, stenoparib, contributing to a negative outlook on the stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.